Mode
Text Size
Log in / Sign up

Viral pneumonia

Part of Pneumonia

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for viral pneumonia

5 trials tracked for viral pneumonia: 1 in phase 3 or 4 and 1 with published results. The most-cited published study has 12 citations.

5Trials tracked
1Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 1 Phase 2 2 Phase 1 1 Other / NA 1
  1. Phase 3 Study on Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients With Severe COVID-19 Pneumonia. Completed · 12 cited
  2. Phase 2 Efficacy, Safety, Tolerability, and Biomarkers of Ibudilast (MN-166) in Patients Hospitalized With COVID-19 at Risk for ARDS Completed
  3. Phase 2 Inhalation Low Dose Radionuclide Therapy in Treatment COVID-19 Completed
  4. Phase 1 A Phase 1/2 Safety and Immunogenicity Trial of COVID-19 Vaccine COVIVAC (Phase 1) Completed
  5. N/A Effect of Respiratory Exerciser on Pulmonary Functions of COVID-19 Patients Completed

Showing the 5 most-cited and recently-updated of 5 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Viral pneumonia: what the trials found

Clinical data regarding Reparixin in patients with viral pneumonia did not demonstrate a statistically significant difference in the proportion of patients alive and free of respiratory failure at Day 28 (p=0.216) or Day 60 (p=0.377) 1.

Mortality rates up to Day 28 for patients treated with Reparixin did not show a statistically significant difference (p=0.17) 1.

Recent results — preliminary, needs further review

  • Ibudilast was evaluated in a Phase 2 trial regarding hospital discharge rates at days 7, 14, and 28, but results are not yet corroborated 2.
  • 99mTc-pertechnetate aerosol inhalation was assessed for safety monitoring in patients with COVID-19 viral pneumonia, reporting neutrophil percentages ranging from 68.4% to 76.3% 3.
  • COVIVAC was evaluated in a Phase 1 trial measuring Geometric Mean Fold Rise (GMFR) 4.
  • Incentive Spirometer/Respiratory Exerciser was assessed in a small cohort 5.

For the clinician treating this condition

  • Reparixin did not demonstrate statistically significant improvements in survival, freedom from respiratory failure, or mortality rates in patients with viral pneumonia 1.
  • Current evidence for Reparixin does not support its use as a superior intervention for improving clinical outcomes at 28 or 60 days post-treatment 1.

AI synthesis of 5 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Research across Pneumonia

Related studies from across the Pneumonia family.

Higher baseline Prognostic Nutritional Index reduces mortality risk in sepsis and pneumonia patients
Rheumatology Meta-analysis
Higher baseline Prognostic Nutritional Index reduces mortality risk in sepsis and pneumonia patients Nutritional status helps predict survival in patients with severe infections
This meta-analysis of 28,757 patients with infectious diseases found that higher baseline Prognostic Nutritional Index (PNI) is associated w…
A high nutritional score at the start of treatment can help doctors identify which patients with sepsis or pneumonia are at the highest risk…
Omadacycline and baloxavir marboxil used in an 89-year-old with influenza A, psittacosis, and Klebsiella pneumonia
Rheumatology Sys. Review
Omadacycline and baloxavir marboxil used in an 89-year-old with influenza A, psittacosis, and Klebsiella pneumonia New drug combination helps elderly man with severe lung infections
This case report describes an 89-year-old man with influenza A, Chlamydia psittaci pneumonia, and Klebsiella pneumoniae who improved and was…
A combination of omadacycline and baloxavir marboxil helped an 89-year-old man recover from a complex, multi-organ infection in the ICU.
Autoantibody positivity and false-negative cytology can mask invasive mucinous adenocarcinoma in patients with IPAF
Allergy & Immunology Sys. Review
Autoantibody positivity and false-negative cytology can mask invasive mucinous adenocarcinoma in patients with IPAF Lung cancer can mimic autoimmune lung disease in some patients
This case report describes a 78-year-old female with invasive mucinous adenocarcinoma and interstitial pneumonia with autoimmune features. T…
A new case shows how a rare lung cancer can look like an autoimmune disease, making it hard for doctors to tell them apart.
MRSA nares PCR does not cut vancomycin duration in ICU CAP
Infectious Disease RCT
MRSA nares PCR does not cut vancomycin duration in ICU CAP MRSA Testing Does Not Reduce Vancomycin Use in Pneumonia Patients
In a single-center randomized trial of 277 adult ICU patients with suspected community-acquired pneumonia, MRSA nares PCR testing did not si…
A trial of 277 ICU patients found that MRSA nasal swab testing did not reduce the amount of vancomycin used for pneumonia.
Physical frailty tops risk factors for pneumonia after esophagectomy, meta-analysis finds
Geriatrics & Aging Meta-analysis
Physical frailty tops risk factors for pneumonia after esophagectomy, meta-analysis finds Physical frailty and muscle loss increase pneumonia risk after surgery
This meta-analysis of 60 cohort studies in esophageal cancer patients undergoing esophagectomy identified physical frailty as the highest-ra…
Patients with esophageal cancer face a higher risk of pneumonia after surgery if they show signs of physical frailty or muscle loss.
Short-course ceftriaxone reduces hospital stay and adverse events in children with pneumonia
Infectious Disease RCT
Short-course ceftriaxone reduces hospital stay and adverse events in children with pneumonia Shorter antibiotic courses may help children with pneumonia stay home
This randomized controlled trial of 200 children aged 1 to 14 years found that short-course ceftriaxone (5 to 7 days) resulted in shorter ho…
A new trial shows that a shorter course of ceftriaxone can reduce hospital stays and side effects for children with pneumonia.
Aerosolized liposomal amphotericin B provides strongest evidence for invasive pulmonary aspergillosis prophylaxis in high-risk patients
Gastroenterology Sys. Review
Aerosolized liposomal amphotericin B provides strongest evidence for invasive pulmonary aspergillosis prophylaxis in high-risk patients Aerosolized Amphotericin B Shows Promise for Lung Fungal Infections
This mini review synthesizes clinical experience regarding aerosolized antifungal therapies for various pulmonary fungal infections. It conc…
Aerosolized liposomal amphotericin B shows promise for preventing specific lung fungal infections in high-risk and immunocompromised patient…
mNGS achieves 85.83% pathogen detection rate in children with severe pneumonia compared to 49.97% for conventional methods
Pediatrics Sys. Review
mNGS achieves 85.83% pathogen detection rate in children with severe pneumonia compared to 49.97% for conventional methods New Genetic Test Finds More Pneumonia Germs in Kids
This systematic review evaluates metagenomic next-generation sequencing (mNGS) for identifying pathogens in children with severe pneumonia. …
A new genetic test detects pneumonia-causing germs in kids more often than standard methods, which could lead to better treatment.
Inhaled antibiotics may improve lung function and microbiological eradication in cystic fibrosis and bronchiectasis
Infectious Disease Meta-analysis
Inhaled antibiotics may improve lung function and microbiological eradication in cystic fibrosis and bronchiectasis Inhaled Antibiotics May Improve Lung Health in Chronic Lung Conditions
This meta-analysis evaluated the efficacy of inhaled antibiotics for patients with cystic fibrosis, non-cystic fibrosis bronchiectasis, and …
Inhaled antibiotics may improve lung function and clear infections for people with cystic fibrosis and other chronic lung conditions.
Antibiotic exposure disrupts gut microbiota in 58% to 94% of critically ill children
Infectious Disease Sys. Review
Antibiotic exposure disrupts gut microbiota in 58% to 94% of critically ill children Antibiotics and gut health in critically ill children
This narrative review examines antibiotic exposure in critically ill children in the PICU, reporting that 58% to 94% receive antibiotics, wh…
Common antibiotics used in intensive care can disrupt a child's gut health, increasing the risk of serious infections like pneumonia.
iNKT cell activators show promise in preclinical models for stroke-associated pneumonia immunomodulation
Pulmonology & Critical Care Meta-analysis
iNKT cell activators show promise in preclinical models for stroke-associated pneumonia immunomodulation New immune treatments show promise for stroke and pneumonia
This systematic review of 38 preclinical studies examines the immunopathology of stroke-associated pneumonia (SAP) and the role of immunomod…
Researchers identify how stroke triggers immune failure and find a promising new way to protect the lungs from pneumonia infections.
IL-6 overexpression linked to alveolar damage in severe pneumonia on ventilation
Primary Care & Family Medicine Sys. Review
IL-6 overexpression linked to alveolar damage in severe pneumonia on ventilation IL-6 Levels Linked to Lung Damage in Severe Pneumonia
This narrative review synthesizes basic and clinical evidence on IL-6 in mechanically ventilated patients with severe pneumonia. It finds th…
High levels of a protein called IL-6 may be linked to increased lung damage and inflammation in patients with severe pneumonia.